申请人:RIGEL PHARMACEUTICALS, INC.
公开号:US20140303154A1
公开(公告)日:2014-10-09
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
本发明提供了2,4-嘧啶二胺化合物,可抑制导致释放化学介质的IgE和/或IgG受体信号级联反应,提供了合成该化合物的中间体和方法,以及在各种情况下使用该化合物的方法,包括在通过去颗粒化和其他由激活IgE和/或IgG受体信号级联反应引起的释放化学介质的疾病的治疗和预防中使用。